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AIMS
Extended-release niacin (ERN) is the most effective agent for increasing high-density lipoprotein–cholesterol (HDL-C). Having
previously identified anti-HDL antibodies, we investigated whether ERN affected the antioxidant capacity of HDL and whether
ERN was associated with the production of antibodies against HDL (aHDL) and apolipoprotein A-I (aApoA-I).
METHODS
Twenty-one patients older than 18 years, with HDL-C ≤40 mg dl–1 (men) or ≤50 mg dl–1 (women) were randomly assigned to
receive daily ERN (n = 10) or placebo (n = 11) for two sequential 12-week periods, with 4 weeks of wash-out before cross-over.
Primary outcome was change of paraoxonase-1 (PON1) activity and secondary outcomes were changes in aHDL and aApoA-I
antibodies. Clinical Trial Unique Identifier: EudraCT 2006–006889-42.
RESULTS
The effect of ERN on PON1 activity was nonsignificant (coefficient estimate 20.83 U l–1, 95% confidence interval [CI] –9.88 to
51.53; P = 0.184). ERN was associated with an increase in HDL-C levels (coefficient estimate 5.21 mg dl–1, 95% CI 1.16 to 9.25;
P = 0.012) and its subclasses HDL2 (coefficient estimate 2.46 mg dl–1, 95% CI 0.57 to 4.34; P = 0.011) and HDL3 (coefficient
estimate 2.73 mg dl–1, 95% CI 0.47 to 4.98; P = 0.018). ERN was significantly associated with the production of aApoA-I anti-
bodies (coefficient estimate 0.25 μgml–1, 95% CI 0.09–0.40; P = 0.001). aApoA-I titres at baseline were correlated with decreased
PON activity.
CONCLUSIONS
The rise in HDL-C achieved with ERNwas not matched by improved antioxidant capacity, eventually hampered by the emergence
of aApoA-I antibodies. These results may explain why Niacin and other lipid lowering agents fail to reduce cardiovascular risk.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• High-density lipoprotein–cholesterol (HDL-C) is associated with a reduced cardiovascular risk.
• Extended-release niacin (ERN) is the most effective agent for increasing HDL-C levels.
• Clinical studies have not shown a reduction in cardiovascular events by HDL-increasing therapies – the “HDL paradox”.
WHAT THIS STUDY ADDS
• Increased anti-apolipoprotein A-I titres were observed after only 12 weeks of ERN treatment, and were correlated with
HDL-C levels.
• This could lead to reduced biological activity of HDL particles, hampering the protective effect of the increased HDLmass.




This Table lists key ligands in this article that are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal
for data from the IUPHAR/BPS Guide to PHARMACOLOGY [1].
Introduction
Atherosclerosis is a leading cause of cardiovascular morbidity
and mortality. Despite a dramatic reduction in low-density
lipoprotein–cholesterol (LDL-C), treatment with statins is
still associated with a persistent cardiovascular risk [2]. The
protective role of high-density lipoprotein–cholesterol
(HDL-C) against atherosclerosis has been extensively sug-
gested [3], but a clear clinical effect for a persistent increase
of HDL-C is yet to be shown. Extended-release niacin (ERN)
is the most powerful drug in current clinical practice to in-
crease HDL-C (up to 35%) [4]. It also reduces triglycerides
(TG), lipoprotein (a) and LDL-C, favourably changing the size
and number of LDL particles [5]. Furthermore, ERN also dif-
ferentially changes the relative quantity of different HDL
subfractions, which could increase its antiatherogenic action.
Although the mechanisms by which ERN operates these
changes on HDL are not fully understood, it is thought to
reduce the availability of free fatty acid for hepatic VLDL
synthesis, leading to reduced cholesteryl ester transfer pro-
tein activity and increased HDL2/HDL3 ratio [6]. Addition-
ally, it could also decrease the hepatic uptake of HDL
particles [7]. HDL2 has a higher content of apolipoprotein
A-I (ApoA-I), which is associated with an increase in
paraoxonase-1 (PON1) activity [8]. PON1 is an important
component of HDL particles, which can metabolize lipid per-
oxides, not only inside the HDL particle but also in other lipo-
proteins (such as LDL), and even in the atherosclerotic
plaque. Furthermore, PON1 activity has been shown to be re-
duced in several diseases associated with a high cardiovascu-
lar risk, such as diabetes mellitus or renal failure [9].
This “HDL-paradox” has been highlighted by four clinical
trials in patients with optimized LDL-C levels, in whom the
rate of cardiovascular events did not reduce, despite an
increase in HDL-C levels and regardless of the treatment
used [10–14].
Previously, our group has identified antibodies against
HDL (aHDL), which may be a “family” of autoantibodies
with different targets within the lipoprotein that can impair
HDL function [15–18]. We hypothesize that aHDL, or
specifically anti-ApoA-I antibodies (aApoA-I), may be in-
duced by HDL-C-boosting treatments, thus hampering the
antiatherogenic effects expected as a consequence of higher
serum HDL-C levels.
In this study, we aimed to determine the effect of ERN on
the antioxidant capacity of HDL as well as on the production
of aHDL and aApoA-I antibodies, and whether the presence
of the latter was associated with a reduction in HDL’s antiox-
idant activity.
Methods
Study design and participants
This is an exploratory phase II, randomized, double-blind pla-
cebo controlled, single cross-over, investigator initiated trial
conducted in NOVA Medical School, Universidade Nova de
Lisboa, Portugal. The study was approved by the Portuguese
National Ethics Committee for Clinical Investigation (refer-
ence number CEIC 0702BU063), and was performed accord-
ing to the principles of the Declaration of Helsinki and
Good Clinical Practice. The trial was registered with EudraCT
as number 2006–006889-42.
Eligible participants were men or women of any ethnic or-
igin, aged 18 years or older, with serum HDL-C ≤40 mg dl–1 or
≤50 mg dl–1, respectively. Participants were excluded if they
had: allergy to the study drug; a physical or psychological
condition compromising their participation in the trial; a
treatment regimen with statins, fibrates or other lipid-
lowering medication during the 8 weeks prior to enrolment;
serum LDL-C >180 mg dl–1; TG >200 mg dl–1; diabetes
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mellitus or cardiovascular disease; an active peptic ulcer; an
active haemorrhage; a history of drug abuse (except alcohol);
creatinine clearance <60 ml min–1, total bilirubin ≥2 times
the upper limit of normal; aspartate aminotransferase (AST)
and/or alanine aminotransferase (ALT) ≥3 times the upper
limit of normal; participation in another investigational drug
trial within 30 days of enrollment. Women who were preg-
nant, nursing, planning to become pregnant while in the trial
or unable to use effective contraception were excluded.
Patients were recruited from local hospitals and clinics,
and invited to participate in the study, which was performed
at NOVA Medical School, Universidade Nova de Lisboa. All
patients provided written informed consent.
Randomization and masking
Participants were randomly assigned (1:1) using stratified
permuted blocks. Each randomization block was composed
of six patients, with three patients per treatment sequence
(A: ERN/Placebo; B: Placebo/ERN). A list generated by an inde-
pendent clinical research organization (Keypoint Group,
Portugal), contained a code number that identified the se-
quence assigned to each patient included in the trial. A paper
copy of the randomization code list was placed in a sealed
opaque envelope and provided to the Responsible Pharmacist
in order to allow for the preparation of the study drugs and
placebos. Individual sealed opaque code envelopes together
with written instructions for code breaking were provided to
the investigator. Physicians who enrolled participants, using
the sequence generated by the CRO to assign them to the trial
groups, were responsible for all assessments carried out during
the study. ERN and placebo tablets were identical in appear-
ance. Patients, those carrying out interventions (physicians)
and those assessing outcomes (laboratory investigators) were
masked to treatment assignment. Lipid measurements and
the remaining laboratory assessments were performed by
different laboratory investigators. Those analysing the final
data were unblinded.
Study procedures
The study drug was taken orally, daily, at night, for 12 weeks,
at an initial dose of 500mg, which was titrated to amaximum
dose of 1500 mg in the first 7 weeks. After a 4-week wash-out
period (which is considered sufficient considering pharmaco-
kinetic data about ERN and HDL particles), treatment arms
were crossed over and placebo or ERN were given for an
equivalent period of time, followed by a final assessment of
safety and efficacy, 4 weeks after the end of treatment. All par-
ticipants received dietary counselling during the study.
A general evaluation with records of demographics, med-
ical history, concomitant medication and physical examina-
tion, which included height, weight, abdominal perimeter
and blood pressures (variables measured by trained physi-
cians), was performed at baseline and, with the exception of
demographics and medical history, all other data (including
change in concomitant medication or adverse events) were
recorded at every study visit. Serum target parameters were
assessed at baseline, then at weeks 7, 12, 16, 23, 28 and 32.
They included: PON1 activity, nitric oxide metabolites
(NO2
– and NO3
–), total cholesterol (TC), LDL-C and triglycer-
ides (TG), very low-density lipoprotein-cholesterol (VLDL-C),
total HDL-C, HDL2 and 3, ApoA-I and immunoglobulin (Ig)G
aHDL and aApoA-I antibodies. TC, HDL-C, LDL-C and TG
were determined by a colorimetric standard enzymatic reac-
tion (commercial kits: Irlandox; Randox, Porto, Portugal).
VLDL-C was estimated by dividing TG values by 5 (for TG
levels ≤400 mg dl–1). HDL subfractions 2 and 3 were
determined by an enzymatic assay using a QUANTILOP
HDL (HDL2/HDL3) precipitation test reagent. ApoA-I serum
concentration was measured by an immunoturbidimetric
immunoassay (commercial kits: Randox). PON1 activity was
assessed by quantification of nitrophenol formation by
spectrophotometry [19]. Serum nitric oxide metabolites
(NO2
– and NO3
–) were measured using a modified Griess
reaction [20]. Titres of IgG aHDL and IgG aApoA-I antibodies
were assessed by an enzyme-linked immunosorbent assay as
previously described [16–18].
Outcomes
Primary outcome was change of mean PON1 activity in se-
rum from baseline to end of treatment. Secondary endpoints
included changes in lipid profile, aHDL and aApoA-I antibod-
ies and mean serum nitric oxide metabolites.
Safety parameters (full blood count and basic chemistry)
and a 12-lead electrocardiogram were performed at baseline
and at weeks 16 and 32. All adverse events were recorded.
Data management
Data collection, management and monitoring were con-
ducted by an independent clinical research organization
(Keypoint Group, Portugal).
Statistical analysis
We calculated that a sample size of 30 patients in this two-
treatment crossover study would provide 80% power to de-
tect a difference in mean PON1 activity of 250 U l–1 between
the treatments, at a significance level α = 0.05. We initially
aimed to randomize 36 patients with an assumed dropout
rate of 15%. We did intention-to-treat and per protocol anal-
yses; in the latter, we compared outcomes amongst partici-
pants who were compliant with treatment. Compliance was
determined before data reviewing or unmasking. Subjects
who had taken <80% or >120% of the overall prescribed
medication during the active treatment phase were regarded
as noncompliant and were excluded from the per protocol
analysis. Plasma pharmacokinetic measurements of the study
drug were not undertaken.
Summary statistics for categorical variables were pre-
sented by frequencies (n) and percentages (%) and continu-
ous variables were described using mean and standard
deviation or 95% confidence interval, when applicable. Base-
line characteristics between the two groups were analysed
using the Mann–Whitney test (continuous data) and Fisher’s
test (categorical variables). Primary and secondary efficacy
analyses were performed based on the per protocol popula-
tion. To compare treatment effects, linear mixed models were
built to take into account the autocorrelation structure
between longitudinal measures. The linear mixed effects
models were fitted for all outcomes separately. Individual ef-
fect was considered random and fixed effects were treatment
regimen, period effect, baseline measurements and carryover
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effect. Data were pooled between the two treatment phases
after finding no carryover effect. Spearman coefficients were
calculated to analyze correlations between IgG aApoA-I anti-
bodies and PON1 activity, HDL-C and its subfractions, and
IgG aHDL antibodies, before and after treatment with ERN.
A significance level α = 0.05 was considered. All data were
analysed using STATA 13.0. (StataCorp. 2013. Stata Statistical
Software: Release 13. College Station, TX: StataCorp LP.) and
SPSS (Version 21.0) software.
The trial was registered with EudraCT: number 2006–
006889-42.
Results
Between March 1, 2008 and November 30, 2008, we ran-
domly assigned 21 participants to the placebo group (n = 11)
or the ERN group (n = 10), of whom only 17 (81%) completed
the study. Two patients from the placebo group abandoned
clinical follow-up and two patients from ERN group dis-
continued treatment due to the occurrence of adverse events.
In both groups, these patients left the study before reaching
the end of the first period of treatment, so they were excluded
from the final analysis (Figure 1). Baseline demographics,
anthropometry, medical history, lipid profile and biological
variables were similar in both groups (Table 1). Regarding
safety assessments, no significant differences were observed
between groups. No severe adverse events were reported. As
the results from the intention-to-treat and per protocol
analyses were similar, we will only consider the latter.
Effect of ERN treatment on the lipid profile
Patients treated with ERN had a mean estimated increase of
5.21 mg dl–1 (95% confidence interval [CI] 1.16 to 9.25;
P = 0.012) in HDL-C levels, which corresponds to a relative
change of 15.63% in the ERN group, compared to 1.51% in
the placebo cohort (Table 2). Treatment with ERNwas also as-
sociated with a mean estimated increase of 2.46 mg dl–1 (95%
CI 0.57 to 4.34; P = 0.011) in HDL2 levels and 2.73 mg dl–1
(95% CI 0.47 to 4.98; P = 0.018) in HDL3, corresponding to
a relative change of 35.73% and 11.96% in the ERN group
and to a relative change of –2.05% and 3.47% in the placebo
group, respectively. Although not statistically significant,
levels of total cholesterol (P = 0.555), LDL-C (P = 0.298), TG
(P = 0.167) and VLDL (P = 0.167) decreased in the ERN group
when compared to placebo.
Effect of ERN treatment on the HDL anti-
oxidant function and in the levels of anti-HDL
antibodies
No significant effect on PON1 activity was observed after
treatment with ERN in comparison to placebo (Table 2).
Figure 1
Study flow diagram
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Levels of IgG aApoA-I antibodies had a mean estimated in-
crease of 0.25 μg ml–1 (95% CI 0.09–0.40; P = 0.001) after
treatment with ERN, equivalent to a relative change of
93.16% compared with 6.17% in the placebo group.
Although the titres of IgG aHDL antibodies did not differ
between treatment arms, at the end of treatment there was a
positive correlation between these antibodies and aApoA-I
antibodies (r = 0.53, P = 0.03; Figure 2A,B), and between
HDL2 and IgG aApoA-I (r = 0.61, P = 0.009; Figure 2C,D) in
subjects treated with ERN. These subjects also presented a
negative correlation between PON1 activity and IgG
aApoA-I titres at baseline (r = –0.50 P = 0.04), which was lost
at the end of treatment (Figure 2E,F).
No significant differences were found in nitric oxide me-
tabolites levels (P = 0.589) between groups at the end of study,
nor any association with lipid profile or other biological vari-
ables (Table 2).
Discussion
In this pilot trial, ERN administered for the trial period was as-
sociated with an increase in HDL-C, HDL2 and HDL3 when
compared to placebo. Patients treated with ERN had signifi-
cantly higher titres of IgG aApoA-I antibodies, which were
positively correlated with both HDL2 and IgG aHDL at the
end of treatment. Regarding PON1 and NO metabolites,
known as important players in the antioxidant and
antiatherogenic actions of HDL, there were no significant dif-
ferences between the two groups. These findings suggest that
Table 1
Baseline demographic characteristics, clinical and serological data of the two groups
Characteristicsa Placebo(n = 9) ERN(n = 8) P-valueb
Age, y 52.44 (9.55) 46.13 (12.02) 0.248
Sex, female/male n (%) 3 (33.33) / 6 (66.67) 3 (37.50) / 5 (62.50) 1.000
Ethnic origin, black/Caucasian, n (%) 1 (11.11) / 8 (88.89) 0 (0.00)/ 8 (100.00) 1.000
Weight, kg 78.78 (13.51) 82.00 (12.21) 0.500
Height, cm 164 (9.00) 171 (11.00) 0.311
Body mass index, kg m–2 29.09 (3.20) 28.09 (4.68) 0.541
Systolic blood pressure, mmHg 125.78 (14.54) 128.75 (11.86)0 0.629
Diastolic blood pressure, mmHg 75.67 (10.02) 77.50 (6.19) 0.884
Medical history
Hypertension, n (%) 4 (44.44) 2 (25.00) 0.619
Cerebrovascular disease, n (%) 1 (11.11) 0 (0.00) 1.000
Others, n (%) 4 (44.44) 2 (25.00) 0.619
Lipid profile
LDL cholesterol, mg dl–1 138.11 (24.85) 135.75 (23.58) 0.736
Total cholesterol, mg dl–1 198.22 (31.34) 207.38 (30.51) 0.500
Triglycerides, mg dl–1 134.33 (40.71) 127.50 (46.02) 0.847
VLDL cholesterol, mg dl–1 26.84 (8.11) 25.63 (9.22) 0.885
HDL cholesterol, mg dl–1 33.72 (5.74) 34.10 (5.92) 1.000
HDL2, mg dl–1 6.87 (2.25) 6.50 (2.11) 0.885
HDL3, mg dl–1 26.86 (4.47) 27.61 (4.39) 0.923
Apolipoprotein A-I, mg dl–1 133.78(16.62) 130.31 (12.63) 0.773
Biological variables
PON1 activity (U l–1) 344.47 (94.13) 347.30 (97.74) 1.000
NO2
– + NO3
– (μmol l–1) 52.32 (34.72) 52.41 (46.10) 0.606
IgG aHDL (% p. control) 123.42 (64.52) 162.35 (131.66) 0.743
IgG aApoA-I (μg ml–1) 0.40 (0.18) 0.30 (0.09) 0.135
aData are expressed as mean (standard deviation) for continuous data and frequencies (%) for categorical variables.
bDifferences between means were evaluated using Mann–Whitney (continuous data) and Fisher’s exact test (categorical variables).
aApoA-I, anti-apolipoprotein A-I antibodies; aHDL, anti-HDL antibodies; ERN, extended-release niacin; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; NO2
– + NO3
–, nitric oxide metabolites; PON1, paraoxonase 1; VLDL, very low-density lipoprotein
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the increase in HDL-C, HDL2 and HDL3 levels obtained with
ERN did not translate into an increase in the protective capac-
ity of HDL. By allowing also the enhancement of IgG aApoA-I
antibodies, ERN might be contributing to an overall final im-
pairment of HDL’s antioxidant function.
Anti-HDL antibodies are a family of antibodies, the
specificity of which is directed against ApoA-I and PON1
[15–18]. They have been reported in patients with diabetes
[21], cerebrovascular and cardiovascular diseases [22, 23],
Alzheimer’s disease [24] and in different autoimmune condi-
tions [15–17, 25, 26]. They are biologically active [27, 28], and
our group has shown that they can inhibit the physiological
properties of HDL in experimental models [18, 29, 30].
Furthermore, different antibody profiles seem to be associ-
ated with different clinical phenotypes [18].
In this study, there was a significant and robust increase
of the titres of aApoA-I antibodies in the treatment arm.
The fact that after treatment, and not at baseline, the titres
of aApoA-I antibodies and of IgG aHDL were positively cor-
related, suggests that after ERN administration the majority
of aHDL antibodies are directed against aApoA-I. This
might be associated with a predominance of ApoA-I as an
immunogenic particle, or with increased immunogenicity
of the existent ApoA-I molecules. Interestingly, ApoA-I
levels were unchanged between treatment arms, which
could be related to enhanced clearance mediated by the
increased level aApoA-I antibodies, or could support the
latter hypothesis.
Nevertheless, the increased aApoA-I titres after ERN treat-
ment could explain why PON activity did not parallel the in-
crease in HDL, as PON needs ApoA-I to stabilize and improve
its antioxidant activity [31]. Accordingly, aApoA-I titres at
baseline were associated with a reduced PON activity. How-
ever, that correlation, although apparent, did not reach
statistical significance at the end of treatment. This could
be due to a low sample size, which was not powered to detect
this secondary outcome. Alternatively, a weakening of that
correlation could be explained by a saturation of the inhibi-
tory effect of aApoA-I on the PON enhancement by ApoA-I.
In this scenario, upon high aApoA-I titres, PON activity
would be further hampered only by the anti-PON1 fraction
of aHDL, which is expected to be lower after ERN. Lastly,
the possibility that aApoA-I would lose its biological activity
after ERN treatment seems more bizarre and would not ex-
plain the clinical data.
Currently, translational research on HDL shows an ab-
sence of positive results in clinical-focused trials on drugs
that increase HDL-C levels. This “HDL-paradox” highlights
the clear contrast between the protective effects of HDL in
basic-research settings and its inefficacy in clinical trials.
The present results suggest a viable explanation for such a
disparity.
There are some limitations to this study: the sample was
small and the duration of treatment short. Nevertheless,
these limitations would have favoured a negative result, with
a low probability of a functionally relevant production of
Table 2
Effect of 12 weeks of treatment with ERN on the study target parameters
Outcomesa
Placebo ERN ERN treatment effect
Baseline EOT Baseline EOT Coeficient estimate (95%CI) P-valueb
LDL cholesterol, mg dl–1 132.47 (31.20) 140.00 (26.61) 141.53 (25.37) 131.59 (31.18) –7.47 (–21.55 to 6.61) 0.298
Total cholesterol, mg dl–1 199.82 (27.63) 200.67 (35.73) 206.18 (28.60) 196.65 (42.46) –5.88 (–25.41 to 16.65) 0.555
Triglycerides, mg dl–1 127.47 (52.71) 148.40 (59.81) 151.94 (67.86) 127.18 (67.51) –21.06 (–50.96 to 8.84) 0.167
VLDL cholesterol, mg dl–1 25.45 (10.54) 29.68 (11.93) 30.47 (13.57) 25.53 (13.42) –4.21 (–10.19 to 1.77) 0.167
HDL cholesterol, mg dl–1 35.67 (7.40) 35.67 (6.74) 34.25 (4.58) 39.80 (9.30) 5.21 (1.16 to 9.25) 0.012c
HDL2, mg dl–1 7.69 (2.86) 7.19 (2.46) 6.38 (1.68) 8.59 (3.82) 2.46 (0.57 to 4.34) 0.011d
HDL3, mg dl–1 27.97 (5.05) 28.47 (5.17) 27.88 (3.69) 31.20 (6.02) 2.73 (0.47 to 4.98) 0.018e
Apolipoprotein A-I, mg dl–1 135.91 (18.16) 136.90 (18.66) 133.26 (10.95) 133.50 (23.49) –4.47 (–12.03 to 3.09) 0.246
PON1 activity (U l–1) 333.09 (101.84) 329.06 (98.65) 331.25 (97.96) 349.01 (111.50) 20.83 (–9.88 to 51.53) 0.184
NO2
– + NO3
– (μmol l–1) 52.87 (37.01) 45.84 (35.05) 55.75 (38.80) 54.10 (53.68) –8.52 (–39.48 to 22.43) 0.589
IgG aHDL antibodies
(%p. control)
126.47 (67.30) 116.46 (84.15) 132.52 (101.63) 127.25 (61.33) 13.05 (–9.53 to 35.62) 0.257
IgG aApoA-I antibodies
(μg ml–1)
0.36 (0.14) 0.35 (0.07) 0.33 (0.11) 0.59 (0.32) 0.25 (0.09 to 0.40) 0.001
aData are expressed as mean (standard deviation).
bERN treatment effect was calculated using linear mixed effects models and is presented as coefficient estimate (95% confidence interval).
cHDL cholesterol levels at baseline remained in the multivariable model;
dPeriod effect and HDL2 levels at baseline remained in the multivariable model;
eHDL3 levels at baseline remained in the multivariable model.
aApoA-I, anti- apolipoprotein A-I antibodies; aHDL, anti-HDL antibodies; EOT, end of treatment; ERN, extended-release niacin; HDL, highdensity
lipoprotein; LDL, low-density lipoprotein; NO2
– + NO3
–, nitric oxide metabolites; PON1, paraoxonase 1 and VLDL, very low-density lipoprotein.
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Figure 2
Correlation between anti-apolipoprotein A-I antibodies titres and target parameters at baseline and end of treatment in ERN group. Spearman’s
correlation between IgG anti-apolipoprotein A-I (aApoA-I) and IgG anti-high density lipoprotein (aHDL) antibodies at (A) baseline and (B) the end
of treatment, HDL2 levels at (C) baseline and (D) the end of treatment and paraoxonase 1 (PON1) activity at (E) baseline and (F) end of treatment
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antibodies in such a short period of time. The significant in-
crease of HDL-C, HDL2 and HDL3 unmatched by an increase
in the functional activity of HDL points towards the neutral-
izing capacity hence the relevance of these antibodies. Addi-
tionally, plasma pharmacokinetic measurements were not
made, which could have improved the determination of com-
pliance to the study drug.
The effect of lipid-modifying agents on antibodies toward
HDL components had never been studied. We put forward
the possibility that under oxidative and proinflammatory set-
ting, a drug-induced increase in HDL-C concentrations could
lead to increased aHDL or aApoA-I antibody production, thus
abrogating the expected clinical results in trials on niacin.
This may be a major breakthrough in understanding why
treatments targeting HDL-C have not been effective in the
clinical setting. Identifying patients with aApoA-I antibodies
as well as defining their pathogenic role may help to design
better trials and find better strategies for HDL-C interventions
in the future.
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